Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.

ACE2 binding Omicron subvariants SARS-CoV-2 humoral responses temperature

Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
02 Jul 2024
Historique:
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

The continued evolution of severe acute respiratory syndrome 2 (SARS-CoV-2) requires persistent monitoring of its subvariants. Omicron subvariants are responsible for the vast majority of SARS-CoV-2 infections worldwide, with XBB and BA.2.86 sublineages representing more than 90% of circulating strains as of January 2024. To better understand parameters involved in viral transmission, we characterized the functional properties of Spike glycoproteins from BA.2.75, CH.1.1, DV.7.1, BA.4/5, BQ.1.1, XBB, XBB.1, XBB.1.16, XBB.1.5, FD.1.1, EG.5.1, HK.3, BA.2.86 and JN.1. We tested their capacity to evade plasma-mediated recognition and neutralization, binding to angiotensin-converting enzyme 2 (ACE2), their susceptibility to cold inactivation, Spike processing, as well as the impact of temperature on Spike-ACE2 interaction. We found that compared to the early wild-type (D614G) strain, most Omicron subvariants' Spike glycoproteins evolved to escape recognition and neutralization by plasma from individuals who received a fifth dose of bivalent (BA.1 or BA.4/5) mRNA vaccine and improve ACE2 binding, particularly at low temperatures. Moreover, BA.2.86 had the best affinity for ACE2 at all temperatures tested. We found that Omicron subvariants' Spike processing is associated with their susceptibility to cold inactivation. Intriguingly, we found that Spike-ACE2 binding at low temperature was significantly associated with growth rates of Omicron subvariants in humans. Overall, we report that Spikes from newly emerged Omicron subvariants are relatively more stable and resistant to plasma-mediated neutralization, present improved affinity for ACE2 which is associated, particularly at low temperatures, with their growth rates.IMPORTANCEThe persistent evolution of SARS-CoV-2 gave rise to a wide range of variants harboring new mutations in their Spike glycoproteins. Several factors have been associated with viral transmission and fitness such as plasma-neutralization escape and ACE2 interaction. To better understand whether additional factors could be of importance in SARS-CoV-2 variants' transmission, we characterize the functional properties of Spike glycoproteins from several Omicron subvariants. We found that the Spike glycoprotein of Omicron subvariants presents an improved escape from plasma-mediated recognition and neutralization, Spike processing, and ACE2 binding which was further improved at low temperature. Intriguingly, Spike-ACE2 interaction at low temperature is strongly associated with viral growth rate, as such, low temperatures could represent another parameter affecting viral transmission.

Identifiants

pubmed: 38953636
doi: 10.1128/mbio.00907-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0090724

Auteurs

Mehdi Benlarbi (M)

Centre de Recherche du CHUM, Montréal, Québec, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

Shilei Ding (S)

Centre de Recherche du CHUM, Montréal, Québec, Canada.

Étienne Bélanger (É)

Centre de Recherche du CHUM, Montréal, Québec, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

Alexandra Tauzin (A)

Centre de Recherche du CHUM, Montréal, Québec, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

Raphaël Poujol (R)

Montreal Heart Institute, Research Center, Montreal, Quebec, Canada.

Halima Medjahed (H)

Centre de Recherche du CHUM, Montréal, Québec, Canada.

Omar El Ferri (O)

Department of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.

Yuxia Bo (Y)

Department of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.

Catherine Bourassa (C)

Centre de Recherche du CHUM, Montréal, Québec, Canada.

Julie Hussin (J)

Montreal Heart Institute, Research Center, Montreal, Quebec, Canada.
Département de Médecine, Université de Montréal, Montréal, Québec, Canada.
Mila-Quebec AI institute, Montreal, Quebec, Canada.

Judith Fafard (J)

Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.

Marzena Pazgier (M)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

Inès Levade (I)

Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.

Cameron Abrams (C)

Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.

Marceline Côté (M)

Department of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.

Andrés Finzi (A)

Centre de Recherche du CHUM, Montréal, Québec, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

Classifications MeSH